|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Furthermore, missense mutations in the key genes IL-13, IL-13Rα1, IL-13Rα2, IL-4, IL-4Rα are common, while no case reports have been published on any immune deficiency or increased risk of neoplastic disease associated with such mutations, suggesting that these genes do not harbor non-redundant roles in adult outbred humans.
|
30759882 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, IL-4R-targeted CTLs efficiently inhibited melanoma growth and reversed the immunosuppressive tumor microenvironment.
|
29329051 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Importantly, IL-4Rα silencing also significantly suppressed tumor growth in vivo.
|
28350325 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Upregulation of IL4 receptor (IL4R) is observed in diverse tumors and TAMs.
|
28878029 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Interleukin-4 receptor-targeted delivery of Bcl-xL siRNA sensitizes tumors to chemotherapy and inhibits tumor growth.
|
28732245 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study investigated the ability of a tumour-targeting IL-4Rα aptamer-liposome-CpG ODN delivery system to introduce CpG into tumours and overcome the immunosuppressive TME.
|
27819142 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The specific targeting of interleukin-4 receptor α (IL4Rα) receptor offers a promising therapeutic approach for inhibition of tumor cell progression in breast cancer patients.
|
27456946 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We demonstrated that IL-4Rα was overexpressed in 36/50 (72%) ATC, 20/35 (57%) WDFC, and 11/37 (30%) WDPC tumors.
|
26645899 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Similarly, 9% stage I tumors were positive for IL-4Rα (≥ 2+) compared to 84% stage II (P ≤ 0.0001) and 100% stages III-IV tumors (P ≤ 0.0001).
|
25208941 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, intratumoral administration of IL-4Rα-lytic hybrid peptide significantly inhibited tumor growth in a xenograft model of human HNSCC in vivo.
|
23563734 |
2013 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Mice with global deletion of IL4Ra had significantly fewer and smaller tumors.
|
20176658 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Interleukin-13 receptor alpha2 (IL-13Ralpha2) is a tumor antigen that is overexpressed in certain human tumors.
|
20068108 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, malignant brain tumors have been found to overexpress a glioma-associated receptor, interleukin-13 receptor alpha2 chain (IL-13Ralpha2), a marker of both glial transformation and tumor grade.
|
17328684 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Interleukin 13 receptor alpha2 (IL-13R(alpha)2) chain is highly expressed on some tumor cell lines and primary cell cultures.
|
11748276 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas.
|
10728667 |
2000 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The results of this study together with the reported increased expression of IL-4R in epithelial neoplasias suggest an association between overexpression of IL-4R and abnormal keratinocyte activation and proliferation.
|
8623919 |
1996 |